Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01498185 · ClinicalTrials.gov registry record · Phase 2
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT01498185 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 171 participants.
The verdict
NCT01498185, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
Interventions
- DRUG Dapagliflozin
- DRUG Placebo matching Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01498185
The ClinicalTrials.gov registry entry for NCT01498185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT01498185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01498185 about?
NCT01498185 is a clinical study titled "BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes". To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
What is the current status of trial NCT01498185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2012-02. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01498185?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo matching Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01498185?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.